Stockreport

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones [Yahoo! Finance]

Tenaya Therapeutics, Inc.  (TNYA) 
PDF Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 D [Read more]